Please login to the form below

Not currently logged in
Email:
Password:

ThromboGenics

This page shows the latest ThromboGenics news and features for those working in and with pharma, biotech and healthcare.

NICE backs Novartis/ ThromboGenics’ eye drug

NICE backs Novartis/ ThromboGenics’ eye drug

It is also good news for the drug's original developers ThromboGenics, which sold non-US rights for Jetrea to Novartis in 2012 in a deal worth up to 375m, and ... progressive disease much earlier and  as soon as patients  start experiencing symptoms

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest appointments

  • ThromboGenics bolsters leadership team ThromboGenics bolsters leadership team

    Appoints Susan Schneider as CMO and Vinciane Vangeersdaele as CCO. ThromboGenics has strengthened its senior leadership team with the appointment of Susan Schneider, who joins the Belgian biotech as its chief ... Patrik De Haes, chief executive officer,

  • ThromoboGenics appoints Thomas Clay as chairman of the board ThromoboGenics appoints Thomas Clay as chairman of the board

    He moves from his previous position as non-executive director. Belgium-based biotech ThromboGenics has appointed non-executive director Thomas Clay as its new chairman of the board and succeeds Staf ... Clay has been a non-executive director of

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics